RESP-X

News

UK biotech Infex is in hot pursuit of Insmed's Brinsupri, the only approved therapy for non-CF bronchiectasis, with its quarterly-dosed antibody.

News

Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.